BCL2 and melanoma: Classically, IHC-mediated routine identification of melanocytic lesions include the use of melanocyte and melanoma markers, like tyrosinase (TYR) and tyrosinase-related proteins (TYRP1 and DCT), gp100 and Melan-A [50]; nonetheless, the utility of a combined immunohistochemical analysis including Bcl-2, nuclear S100A4, Ki67 and MITF to improve the risk stratification of early-stage malignant melanoma patients has been recently reported [36].